| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $85K | — | -96.2% |
| SG&A Expense | $1.6M | -14.2% | -26.4% |
| Operating Income | -$1.6M | +14.2% | +64.0% |
| Net Income | -$1.5M | +70.8% | +64.2% |
| EPS (Basic) | -$0.40 | +61.2% | +52.9% |
| EPS (Diluted) | -$0.40 | +61.2% | +52.9% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $5.4M | -16.7% | -47.2% |
| Current Assets | $5.7M | -22.2% | -51.9% |
| Total Assets | $9.7M | -15.1% | -52.9% |
| Current Liabilities | $1.5M | -16.2% | -29.6% |
| Total Liabilities | $3.2M | -13.7% | -32.6% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.5M | — | — |
| Investing Cash Flow | $320K | — | — |
| Financing Cash Flow | $3.3M | — | — |
| $6.5M |
| -15.8% |
| -59.1% |